Floatz logo

Golcadomide

Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type

Mayo ClinicSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

23 Active assets in the Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type cohort.

Asset / SponsorPhaseRating
Inno-206
Li Zhiming
Phase 2/3BB
PREDNISONE TABLETS
National Cancer Institute (NCI)
Phase 2/3BB
Cyclophosphamide
Li Zhiming
Phase 2/3BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Mayo Clinic
Phase 2/3BB
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3BB

View all 24 →

Same molecule, other indications

Golcadomide is also rated in:

diffuse large B-cell lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
follicular lymphomaDormant
BB
Indicative ·
65 / 100
View asset →
large B-cell lymphomaDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →